2023
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method
Ngufor C, Yao X, Inselman J, Ross J, Dhruva S, Graham D, Lee J, Siontis K, Desai N, Polley E, Shah N, Noseworthy P, MN; New Haven C. Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method. American Heart Journal 2023, 260: 124-140. PMID: 36893934, PMCID: PMC10615250, DOI: 10.1016/j.ahj.2023.02.015.Peer-Reviewed Original ResearchConceptsOral anticoagulantsAtrial fibrillationPatient subgroupsComposite outcomeIschemic strokeEffect of OACsLifelong oral anticoagulationNonvitamin K antagonistNew oral anticoagulantsNonvalvular atrial fibrillationPrimary composite outcomeGlomerular filtration rateFuture prospective studiesOptumLabs Data WarehousePopulation-level effectivenessOAC useOral anticoagulationVASc scoreCause mortalityK antagonistsPrimary endpointWarfarin usersRenal functionAF patientsEntire cohort
2020
Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT)
Pareek M, Byrne C, Vaduganathan M, Biering-Sorensen T, Krogager M, Kragholm K, McCullough M, Desai N, Olsen M, Bhatt D. Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal 2020, 41: ehaa946.2731. DOI: 10.1093/ehjci/ehaa946.2731.Peer-Reviewed Original ResearchSystolic Blood Pressure Intervention TrialIntensive blood pressureSerum bicarbonate levelsBlood pressureBaseline bicarbonateBicarbonate levelsCV causesAntihypertensive treatmentSystolic blood pressure 130End-stage renal diseaseStandard antihypertensive treatmentHigh cardiovascular riskChronic kidney diseaseGlomerular filtration rateRisk of deathStandard blood pressureLow bicarbonate levelsYears of ageMultivariable adjustmentCardiovascular riskSerum bicarbonateRenal diseaseLaboratory variablesPrognostic implicationsIntervention trialsBaseline and on-treatment serum potassium and mortality in high risk patients: the Systolic Blood Pressure Intervention Trial (SPRINT)
Byrne C, Pareek M, Biering-Soerensen T, Vaduganathan M, Krogager M, Kragholm K, McCullough M, Desai N, Olsen M, Bhatt D. Baseline and on-treatment serum potassium and mortality in high risk patients: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal 2020, 41: ehaa946.2732. DOI: 10.1093/ehjci/ehaa946.2732.Peer-Reviewed Original ResearchSystolic Blood Pressure Intervention TrialIntensive blood pressure loweringBlood pressure loweringSerum potassium levelsIntensive blood pressureSerum potassiumPressure loweringPotassium levelsCV causesMultivariable adjustmentBlood pressureSystolic blood pressure 130End-stage renal diseaseBaseline serum potassiumLong-time mortalityShort-time mortalityStandard antihypertensive treatmentHigh cardiovascular riskHigh-risk patientsGlomerular filtration rateYears of ageSerum potassium measurementsAntihypertensive treatmentCardiovascular riskRenal function